Object. The treatment of solitary vestibular schwannomas by performing Gamma Knife surgery is well established. It has been reported that decreasing the surface dose reduces patient morbidity, especially facial weakness and numbness. The authors of this retrospective study examine patient data from a single center to determine if low-dose (Յ 14 Gy) GKS controls tumor growth as effectively as higher doses (Ͼ 14 Gy).
G AMMA Knife surgery is now an accepted treatment for VSs less than 3 cm in diameter. 8 The acceptance of radiosurgery as an alternative to resection is based on its lower rate of patient morbidity and its acceptable control of long-term tumor growth. 3, 7 Authors of initial reports on the results of GKS for VS noted significant morbidity, particularly facial weakness and numbness, frequently enough to cast doubt on the method. In recent years, these side effects have been reduced to very low rates with the use of better imaging and lower doses of radiation (10) (11) (12) (13) (14) at the tumor surface. 5 Because of the concern that lower doses of radiation may not provide adequate long-term control of tumor growth 9 , we undertook this retrospective study of patients treated at a single center since 1989. We compared tumor Abbreviations used in this paper: GKS = Gamma Knife surgery; MR = magnetic resonance; MSD = mean single dose; VS = vestibular schwannoma.
control in patients treated with a surface dose of 14 Gy or less with those in whom higher doses were prescribed.
Clinical Material and Methods

Patient Population
One hundred eighty-nine patients were treated using GKS between December 1989 and July 2004. Follow-up data were available for 159 patients (84.1%). The patients were treated by a group of four neurosurgeons and three radiation oncologists. Patient data were recorded in a customized database. Follow-up evaluation, including contrast-enhanced MR imaging, was routinely requested at 6 months, 1, 2, 3, 4, and 5 years posttreatment, and every 2 to 3 years thereafter. Patients who were lost to follow-up review were from out of town and returned to their local physician; although follow-up records on those patients were requested, they were often missing.
Low-dose Gamma Knife surgery for vestibular schwannoma All patients whose information was recorded in the database and in whom a VS had been diagnosed were included in this study. To minimize any bias, a trained research nurse examined all patient records and independently verified all measurements used in the analysis.
The 159 patients included for study had a mean age at the time of GKS of 59.5 Ϯ 14.2 years (range 22-89 years); 89 (56%) were women. The location of the tumors was nearly evenly distributed, with 46.5% on the left side and 53.5% on the right. Fifty-five patients had simple intracanalicular tumors, with a mean volume of 3.3 Ϯ 4.3 cm 3 (median 1.9 cm 3 ; maximum 33.5 cm 3 ). Seventy-nine percent of the tumors had volumes less than 5 cm 3 , another 11% were between 5 and 8 cm 3 , and 10% were more than 8 cm 3 .
Gamma Knife Surgery
Dose planning usually led to using the 50% isodose shell at the surface, which produces the greatest dose fall off immediately outside the tumor and should be associated with the lowest incidence of side effects. In some cases, better coverage was achieved by using an isodose shell of less than 50% on the surface, but rarely less than 40%. In other cases, to reduce the "hot spot" within the tumor, a higher percentage isodose shell was used on the tumor surface, usually in patients with good hearing, so as to reduce the risk of damage to the cochlear nerve, assuming it might be within the tumor. The trade off is a slower fall off of radiation outside the tumor, which increases risk to the brainstem and surrounding cranial nerves. In this study the mean (and median) isodose value was 50% with a range from 30 to 80%. The majority of patients (65%) were treated with the 50% isodose shell on the surface. The next most frequent isodose shell used on the tumor surface was the 40%, which was used in 17% of patients. Twelve percent of patients were treated with a greater than 60% isodose shell and 6% were treated with a lower than 40% isodose shell at the surface. The highest isodoses were applied in patients with preserved hearing and small tumors.
To minimize patient morbidity, the authors of radiation protocols recommend that users try not to exceed a 14-Gy MSD, except in patients with very small tumors. 5 We started to use low-dose treatments as early as 1989 when we began performing GKS, based on the European experience (G Noren, personal communication, 1989). All doses reported in this study are surface doses. The surface (or edge) dose and the total dose used were influenced by the size of the tumor, with smaller doses being preferred in larger tumors.
Patients in this study are divided into two groups: those receiving a low MSD of 14 Gy or less and those receiving a high MSD of more than 14 Gy, regardless of the percentage isodose shell used on the tumor surface.
Generally we found that large tumors or those touching the brainstem were allocated to the low-dose group, whereas smaller tumors or those in deaf patients were often treated in the high-dose group.
Patient follow-up review was performed either at our center or by using reports and imaging studies sent from the original referring center. At our center, preoperative and follow-up MR studies were performed with 1.5-mm volumetric images, and 1-mm thick computerized tomography scans. Follow-up images sent from other centers were nearly always MR images, but quality and slice thickness were variable, making precise tumor volume measurements difficult.
Statistical Analysis
Data were extracted from the database and imported into SAS version 9.1.3 (SAS Institute, Cary, NC) for analysis. Categorical variables were compared using chisquare analysis and reanalyzed using the Fisher exact test. Continuous variables were compared using the Student t-test.
Tumor ellipsoid volumes were calculated using the x, y, and z axes of each tumor in millimeters. The formula used was: 4/3 (x/2)(y/2)(z/2).
At follow up, the tumor volume measured was compared with the pre-GKS volume. Tumor volumes that had increased more than 40% were classified as "enlarged," those within Ϯ 40% of the pre-GKS volume were classified as "stable," and those that had decreased more than 40% were classified as "smaller."
Results
Overall Treatment of VSs
Tumor volumes were measured at each follow-up visit and then calculated as a percentage of the pre-GKS volume. Figure 1 shows a monotonic decrease over time after the treatment. The data also confirm previous observations that VS will often enlarge initially during the 1st year or so after GKS. 2 The data at 15 years represent one patient followed for that period.
Overall, the mean surface radiation dose for all tumors was 13.6 Ϯ 2.1 Gy (median 14 Gy; range 8-20 Gy). At the time of treatment, the mean volume was 3.3 Ϯ 4.3 cm 3 and at the last follow-up visit, the mean volume was 2.0 Ϯ 2.7 cm 3 , a decrease of 39.4%. The median volume dropped from 1.9 to 0.97 cm 3 , a decrease of 49%. Treatment of VSs with GKS resulted in 73 (45.9%) of 159 tumors being at least 40% smaller at the patient's last follow-up examination, with seven (4.4%) of 159 having grown 40% or more at the last follow up. The remaining 79 (49.7%) of 159 tumors changed less than 40% from pre-GKS volume measurements. Six of the seven patients with tumors that "enlarged" when last seen were followed for 5 years or less; follow up for the seventh patient was 6 years. Table 1 shows the percentage of tumors that were enlarged, stable, or smaller at each follow-up visit.
Treatment of tumors with diameters of 3 cm or more has been controversial, with some surgeons believing these large tumors do not respond to GKS. This study includes eight patients in whom at least one tumor had a diameter of 3 cm or greater. After treatment and follow up, the mean diameter had been reduced from a pre-GKS value of 3.34 cm to a value of 2.41 cm, a reduction of 27.9%. This reduction was somewhat less than the measured improvement in volume for all tumors treated. This group of patients with large-diameter tumors were followed up for a median of 5 years. 
Comparison of Results of Low-and High-Dose GKS
To compare the results of treating VSs with lower radiation doses (specifically ≤ 14 Gy) when appropriate, the data were analyzed according to the surface radiation dose, regardless of the isodose shell value. Table 2 shows the demographics of the resulting groups.
The radiation response of the low-and high-dose groups is compared in Fig. 2 .
The mean initial volume of the tumors in the low-dose group was 3.9 Ϯ 4.8 cm 3 and at the last follow-up visit it by the treatment, a decrease of 47.4%. The change in the median tumor volume was from a pre-GKS value of 1.3 cm 3 to a last follow-up value of 0.45, a decrease of 65.4%. Table 3 shows the percentage of patients who had stable, enlarged, or smaller tumors at the last follow-up visit when compared with their pre-GKS volumes. Figure 3 shows a histogram of the tumor size change and percentage of patients exhibiting that amount of change. The graph indicates that some tumors have increased and much larger numbers of lesions have decreased in volume. Figure 4 is a Kaplan-Meier survival plot of the change in volume at the last follow up, showing when the patients' tumors had progressed by 40% or more. The curves are not statistically different (p = 0.26; log-rank test).
Twenty-one patients died during the 15-year follow-up period, none due to their VS.
Long-Term Follow-Up Review
Sixty-four patients were followed up for 5 years or more after treatment. Data on tumor responses to GKS according to low and high doses of radiation are shown in Table 4 . No significant difference was found in relation to the dose of radiation administered.
Patients who have been followed up for longer than 5 years after treatment had decreases in tumor volume of 62.3% for low-dose and 64.1% for high-dose treatment. The median volumes decreased 71.8% and 74.0% for the Low-dose Gamma Knife surgery for vestibular schwannoma groups, respectively. The changes were not statistically different.
Five patients had tumors that had increased in volume at the last follow up compared with their sizes 5 years after treatment. Four were treated with low-dose radiation and one with a high dose. In all cases, the tumor at the last follow up was more than 40% smaller than the pre-GKS volume.
Discussion
Because the percentage of patients who were followed up was similar in the low-and high-dose groups, it seems unlikely that the two groups differ significantly in outcomes. Therefore, we believe we have good evidence that a low MSD of 14 Gy or even less does not significantly reduce the rate of growth control in GKS.
Complete description of the dose in GKS requires two numbers, one for the MSD and one for the maximum dose, as the dose gradually increases to 100% at some point within the tumor. Another way to describe dosage is to give the surface dose and the percentage of the total dose (the isodose shell) given at the surface. The surface dose is the minimum dose given to the tumor and also the maximum dose to a facial nerve on its surface. As mentioned earlier, studies have shown that complications are reduced when the radiation dose is decreased. Of course, that would not be worthwhile if tumor control has to be compromised. We found no significant difference in long-term tumor response to GKS between the lowand high-dose groups. The insignificant data trend toward more reduction in tumor size with lower doses is probably due to observer error. More of the low-dose tumors were larger and it is easier to measure small size decreases in larger tumors than in the smaller ones, particularly the intracanalicular tumors.
The follow up of the high-and low-dose groups was statistically significant for the whole data set (low 3.5 Ϯ 2.8 compared with high 5.8 Ϯ 3.6 years; p Ͻ 0.001), indicating an increasing use of low-dose protocols as the study went on. Patients will continue to be followed up to determine if the results are the same in the longer term; however, in the subgroup of patients who have been observed for at least 5 years, the means no longer differ statistically (low 6.8 Ϯ 2.3 compared with high 8.0 Ϯ 2.8 years; not significant). In this group, the results are equivalent between the dose levels, which suggests that a longer mean follow-up time will not change the conclusions.
We treated eight patients with tumors larger than 3 cm in diameter; all received low doses, and tumor growth was controlled in seven of them. One patient who harbored a 4-cm tumor and had ankylosing spondylitis underwent suboccipital craniectomy, the success of which was thought to be impossible because of the lack of neck flexibility. He was given a 10-Gy MSD; however, 1 year later the tumor had not decreased in size. A cyst had formed and brainstem compression developed. A subtotal resection was accomplished with great difficulty and he improved. At the 13-year follow up, no evidence of residual tumor can be seen.
The 50% isodose shell was most often used at the surface because that is the steepest part of the slope of the bell-shaped curve seen when the combined dose profile is plotted in two dimensions. Therefore, using the 50% isodose shell on the surface gives the greatest dose falloff immediately outside the tumor and should be associated with the lowest incidence of side effects. The isodose shell used at the surface affects the maximum central dose, assuming the same surface dose is prescribed. In some cases, better coverage was achieved by using an isodose shell of less than 50% on the surface, but rarely less than 40%. In other cases, to reduce the "hot spot" within the tumor, a higher percentage isodose shell was used on the tumor surface, usually in patients with good hearing. This tactic would reduce the risk of damage to the cochlear nerve, assuming it might be within the tumor. The trade-off is a slower falloff of radiation outside the tumor, with increased risk to the brainstem and surrounding cranial nerves. We did not have enough follow-up data to analyze the effect of the percentage of isodose shell used on results.
The advantages of using lower tumor margin doses for treating VSs have been reported in the literature, including reduced morbidity of the facial and trigeminal nerves and unchanged hearing levels for the patient after treatment. The authors of several studies, including this one, have looked at the effectiveness of these reduced doses in treating the tumors. Untreated tumors have a high likelihood of continued progression, with 43% showing continuing growth as documented in a metaanalysis of 21 studies. 10 Eventually 20% of these tumors required further treatment, either radiation or surgery, during the studies' follow-up periods, which averaged only 3.2 years. Longer follow-up periods would likely have shown significantly higher failure rates, approaching the 43% that were progressing.
In this study, the three axial dimensions of the tumor were measured, and the volume was calculated using the formula for an ellipse. To account for the inaccuracy in measuring distances on the small MR images, we used a window of 40% centered on the pre-GKS volume to define a stable tumor size, as the reduction of a 10-mm tumor to 9 mm is a Ϫ37% change in volume. Therefore, we considered changes greater than 40% to be evidence of progression or at the other extreme, destruction of the tumor. Only 5.2% of tumors treated with a low dose and 2.3% of tumors treated with a high dose had increased more than 40% over the pre-GKS volume measurement when seen at the last follow up of 3.6 and 5.8 years, respectively. The difference in the proportion of patients in whom tumor was progressing was not statistically significant between the low-and high-dose groups.
A wide range of criteria reported in the literature are used to assess success of treatment. Using freedom from tumor resection as a criterion, Flickinger, et al., 3 reported success rates of 98.6 and 93.5% based on imaging-defined progression (increase of ≥ 1 mm in two dimensions or 2 mm in any dimension). In the metaanalysis, authors of seven studies used the single greatest diameter as the 6 reported a control rate of 94% at 37 months based on measurements made in their MR imaging studies in 48 patients. By categorizing any increase in measurement based on a three measurement average, Isihara and coworkers 4 reported a 94% control rate at 31.9 months of follow up in 38 patients.
Chung, et al., 1 used a window of Ϯ 10% of the initial volume to define stable, with greater changes leading to increased or decreased classification types.
Tumors in the low-dose group were larger on average than those in the high-dose group as a result of selection bias arising from the dose-volume relationship for side effects, as we attempted to minimize tissue damage to adjacent areas. 2 Our study illustrates that a group of neurosurgeons in private practice at a nonacademic institution can get excellent results. The use of GKS is a safe and effective treatment that can be used effectively by neurosurgeons in any setting.
This study does have a number of limitations. Most of the patients were from other cities and states and followup evaluation depended on obtaining reports or copies of imaging studies performed at other facilities, as most patients would not return to us for neuroimaging. Particularly after 5 years, patients would refuse to undergo an expensive MR imaging study, saying they seemed well and were not concerned. Thus, our effort to maintain complete records was not successful, even after repeated letters and phone calls, which affected the completeness of the data. For similar reasons we were unable to obtain adequate follow-up data to analyze with confidence for patients with hearing impairment.
